Atossa Therapeutics
ATOS
86 hedge funds and large institutions have $226M invested in Atossa Therapeutics in 2021 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 21 increasing their positions, 7 reducing their positions, and 21 closing their positions.
889% more capital invested
Capital invested by funds: $22.8M → $226M (+$203M)
200% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 7
157% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 21
62% more funds holding
Funds holding: 53 → 86 (+33)
17% more call options, than puts
Call options by funds: $84.3M | Put options by funds: $71.8M
0.97% more ownership
Funds ownership: 1.01% → 1.97% (+0.97%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$26.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.11M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$8.98M |
| 4 |
State Street
Boston,
Massachusetts
|
+$7.17M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$6.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$6.97M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$912K |
| 3 |
VF
Virtu Financial
New York
|
-$894K |
| 4 |
Barclays
London,
United Kingdom
|
-$150K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$120K |
ATOS Hedge Fund Activity: Q2 2021 in Review
86 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q2 2021, worth a combined $226M — up 889% from $22.8M a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new ATOS positions and 21 closed out — a net gain of 33 holders — while 21 added to existing stakes and 7 trimmed.
The largest buyer was BlackRock, adding an estimated $26.2M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $6.97M sold.
- 86 institutional investors held Atossa Therapeutics (ATOS) as of Q2 2021, up from 53 in Q1 2021.
- Funds reported $226M of Atossa Therapeutics stock for Q2 2021, up 889% quarter-over-quarter.
- 54 funds opened new Atossa Therapeutics positions in Q2 2021 and 21 closed out, a net change of +33 holders.
- The largest Atossa Therapeutics buyer in Q2 2021 was BlackRock, an estimated $26.2M added.
- The largest Atossa Therapeutics seller in Q2 2021 was Renaissance Technologies, an estimated $6.97M sold.
Based on aggregated 13F filings for Q2 2021.